Remove Heart attacks Remove Heart Disease Remove Innovation
article thumbnail

MMRI Publishes Breakthrough Study Detailing a Novel Approach to Minimize Damage After a Heart Attack

DAIC

associate professor of biomedical research and translational medicine and scientific operations director at MMRI , recently published an innovative manuscript titled, Biomimetic Nanomaterials for the Immunomodulation of the Cardiosplenic Axis Post-Myocardial Infarction. McCarthy, Ph.D. McCarthy, Ph.D., Rajendran JC Bose, Ph.D.,

article thumbnail

National Cardiogenic Shock Initiative Study Results Show Significant Increase in Heart Attack Survival

DAIC

The typical survival rate of this deadly complication during a heart attack has historically hovered around 50%. The National Cardiogenic Shock Initiative is the largest prospective study of therapy for severe heart attack cardiogenic shock done in the United States in the past two decades,” said William O’Neill, M.D.

article thumbnail

Cleerly Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

DAIC

milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its Coronary Artery Disease ( CAD ) Staging System.

article thumbnail

Cleerly Raises $106 Million in Series C Extension Funding

DAIC

Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. We are very excited to see our purpose-driven mission come to life, making advanced cardiac care accessible to more patients and working towards our goal of eliminating heart attacks.” “We

article thumbnail

DAIC's Top 10 for April

DAIC

Clinical trials and innovative technology took center stage during the month of April, racking up some record number views. Incentives Prompt Increased Daily Walking in Patients at Risk for Heart Disease 6. 24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack 10. EMPACT-MI Trial Outcomes Reported at ACC.24:

article thumbnail

Trial Results: Low-Dose Colchicine HelpsTreat Cardiovascular Disease

DAIC

mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heart disease, said Matthew J. mg can prevent heart attack and stroke in high-risk patients with established cardiovascular disease. Budoff, M.D.,

article thumbnail

GE HealthCare and Medis Medical Imaging Announce Collaboration Focused on Non-Invasive Coronary Assessments to Help Advance Precision Care in Treatment of Coronary Artery Disease

DAIC

Within the complex umbrella of cardiovascular disease, CAD is a type of heart disease that develops when the coronary arteries narrow and the heart cannot deliver enough oxygen-rich blood to the heart.